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Abstract
Enzymes are nature’s wizards: balanced delicately on the margin of order and
entropy, they perform chemical reactions and syntheses at rates and yields
human chemists can only dream of. Many possess exquisite control mechanisms
to keep the flow of metabolites through our cells precisely regulated. This work
explores the regulation mechanism of α-isopropylmalate synthase (α-IPMS).
The branched-chain amino acid biosynthetic pathways in bacteria are of
interest as novel antibiotic targets. α-IPMS catalyses the first committed step
in the pathway to form leucine, an essential amino acid. It performs the Claisen
condensation of α-ketoisovalerate (α-KIV) and acetyl coenzyme A (AcCoA) to
form α-isopropylmalate (α-IPM). Almost all previously characterised α-IPMS
enzymes are feedback regulated by leucine, the end-product of this pathway.
This study uses the α-IPMS enzymes from two pathogenic species, Myco-
bacterium tuberculosis and Neisseria meningitidis (MtuIPMS and NmeIPMS,
respectively). These enzymes are homodimeric in solution, and have a catalytic
dimer of (β/α)8 barrels. This is connected via two more subdomains to a
dimerised C-terminal regulatory domain, where leucine binds. The crystal
structures of MtuIPMS with and without leucine bound are almost identical.
Thus, we do not yet fully understand the mechanisms by which leucine is
i
recognised, nor how the allosteric signal is conducted ∼ 50 Å from the regulatory
domain to the active site, and how this disrupts catalysis.
Chapter 2 explores the residues responsible for recognising and binding
leucine. We use insights from the partial crystal structure of a similar enzyme
in Leptospira interrogans, citramalate synthase (CMS). CMS catalyses a similar
reaction to α-IPMS: the condensation of AcCoA and α-ketobutyrate (α-KB)
to form citramalate, as the first step in isoleucine production in this organism.
CMS is feedback regulated by isoleucine just as α-IPMS is regulated by leucine.
CMS also shares a very similar overall structure to α-IPMS, and four conserved
residues in each enzyme were identified as being responsible for binding the
allosteric effector. In previous work, Tyler Clarke1 mutated each of the four
MtuIPMS residues to the corresponding residue from LiCMS in an attempt
to make an isoleucine-regulated MtuIPMS. While one mutant did show an
increased sensitivity to the related amino acid norvaline, none of these mutations
by themselves were sufficient to create an isoleucine-sensitive MtuIPMS. This
work found that by using certain combinations of these mutations, we were able
to create isoleucine-inhibited α-IPMS enzymes.
Dr. Wanting Jiao has been using molecular dynamics simulations to identify
the residues important for allosteric signal propagation and disrupting catalysis
in NmeIPMS . Chapter 3 details several of these residues which we have mu-
tated, and presents the preliminary results of activity and inhibition studies on
the mutant enzymes.
Chapter 4 summarises our findings and outlines the work required to further
our understanding of the allosteric control systems studied here. Adapting
the power of enzymes to contribute to the development of green chemistry,
biosensors, and new antibiotics may prove to be one of the greatest opportunities
ahead of modern chemistry.
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“The problem is so serious that it threatens the achievements of mod-
ern medicine. A post-antibiotic era—in which common infections
and minor injuries can kill—is a very real possibility for the 21st
century.” 2
This chilling prediction from the World Health Organisation is a sharp
reminder that our current arsenal of antibiotics is rapidly being overtaken by
antibiotic resistant strains of bacteria,3 which are developing much faster than
our ability to develop new antibiotics.4,5 While methicillin-resistant Staphylo-
coccus aureus (MRSA) gains a lot of headlines in the developed world, the
spectre of ancient diseases like tuberculosis still haunt the developing world
(tuberculosis still kills more people than any other infectious agent except
HIV/AIDS)6 and look to be making a return to the developed world.7 Clearly,
a lot more research is needed into the mechanisms by which infectious agents
achieve their virulence, and into new ways of stopping them. Understanding
1
CHAPTER 1. INTRODUCTION 2
the intricacies and mechanisms of key enzymes and regulatory pathways is one
approach, and is the theme we explore in this work.
Enzymes responsible for catalysing the synthesis of the branched-chain amino
acids (BCAAs), leucine, isoleucine, and valine, have been identified as potential
drug targets,8 and pursuant to that, the crystal structure of α-isopropyl malate
synthase (α-IPMS) from Mycobacterium tuberculosis was obtained.9 α-IPMS
catalyses the first committed step in the leucine biosynthetic pathway. This
pathway is absent in humans because we obtain all of our leucine from dietary
sources, but genetic knock-out studies10,11 show that this pathway is required
for bacterial growth. The α-IPMS enzyme has proven to be rather interesting:
the catalytic barrel, a fairly typical TIM or (β/α)8 barrel dimer, is allosterically
regulated by a highly unusual regulatory domain so far only found in α-IPMS
and a few related enzymes. While allostery has been studied for decades, it is
only recently that we are beginning to untangle some of the dynamic mechanisms
by which it works. By studying the unusual mechanism of allostery used in this
enzyme, we may open up exciting new opportunities for drug discovery and
development,12 biosensors,13 and provide unique insights into one of the key
aspects of enzyme function.
1.2 Leucine, Isoleucine, and Valine Production:
the Branched-Chain Amino Acid Biosynthetic
Pathways
The branched-chain amino acids are produced by pathways that share many of
the same enzymes, as can be seen in Figure 1.1. All of these pathways start
with pyruvate, derived from glycolysis. Acetohydroxyacid synthase (AHAS)
condenses pyruvate with either another pyruvate molecule or with α-KIV, de-
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rived from threonine via threonine deaminase (TD). The condensation product is
reduced and rearranged by acetohydroxyacid isomeroreductase (AHAIR). This
is then dehydrated by dihydroxyacid dehydratase (DHAD) and transaminated
by branched-chain aminotransferase (BCAT) to form either isoleucine or valine.
Before this final step, α-ketoisovalerate (α-KIV) can be condensed with acetyl
coenzyme A (AcCoA) by α-isopropylmalate synthase (α-IPMS) to form α-
isopropylmalate (α-IPM). The enzyme α-isopropylmalate isomerase (α-IPMI)
rearranges this to β-isopropylmalate, which is oxidised and decarboxylated by
α-isopropylmalate decarboxylase (α-IPMD) to form α-ketoisocaproate. This is
then transaminated by BCAT to form leucine.
1.2.1 Citramalate Pathway
In some organisms, e.g. Leptospira interrogans, an alternative pathway is used
to form α-KB without using threonine as a starting material. Pyruvate is
condensed with AcCoA by citramalate synthase (CMS) to form (R)-citramalate.
The enzyme 2-methylmalate hydrolase (MMH) isomerases (R)-citramalate to
form 3-methyl-D-malate, which is then oxidised by 3-methylmalate dehydroge-
nase (MMD) to form α-KB. This can then proceed via the isoleucine pathway.
This pathway is summarised in Figure 1.2.
1.2.2 Regulation in BCAA Synthesis
The branch-points in these metabolic pathways are, as one would expect, regu-
lated by the end-products. While variations exist between species, the general
trends of regulation are summarised here. TD, the first step committing thre-
onine to be converted to isoleucine, is inhibited by isoleucine.14 In organisms
using the citramalate pathway to product isoleucine, then CMS is inhibited by
isoleucine.15 AHAS, as the main gateway to BCAA production, is regulated
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Figure 1.1: The interconnected branched-chain amino acid biosynthetic path-
ways. The isoleucine pathway is shown in red, valine in blue, and leucine in
green. As can be seen, most of the enzymes here are used for all three pathways.
The position of the citramalate pathway (delineated in Figure 1.2) is shown in
grey. Asterisks denote general trends in feedback regulation by pathway end-
products: red by isoleucine, blue by valine, and green by leucine.
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Figure 1.2: The threonine-independant citramalate pathway to form α-KB, a
precursor required for isoleucine synthesis. The red asterisk indicates CMS is
feedback regulated by isoleucine.
by all three: leucine, isoleucine, and valine.16 Finally, as the branch-point for
leucine synthesis, α-IPMS is inhibited by leucine.
By finely tuning the regulation at each of these metabolic control points,
organisms are able to precisely regulate the flux of metabolites, ensuring their
needs are met, while minimising metabolic waste. The coloured asterisks in
Figure 1.1 summarise which enzymes are regulated by which metabolites.
1.3 α-Isopropylmalate Synthase
α-IPMS (EC 2.3.3.13) is at the branch point between the valine and leucine
biosynthetic pathways. α-KIV either undergoes transamination by BCAT to
become valine, or condensation with AcCoA by α-IPMS to go on to form leucine.
α-IPMS is therefore feedback regulated by leucine to ensure sufficient levels of
both leucine and valine are produced in the cell.
α-IPMS is part of a larger enzyme family of α-ketoacid: AcCoA re-aldolases
(KARA). These catalyse the Claisen condensation of an α-keto acid with Ac-
CoA, and members of this class of enzymes include α-IPMS, citramalate syn-
thase (CMS), homocitrate synthase (HCS), re-citrate synthase (RCS), and methyl-
thioalkylmalate synthase (MAMS).17–20 These enzymes generally require a di-
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valent metal ion for catalysis, which orientates and activates the alpha-carbonyl
for nucleophilic attack.
The leuA gene (most common designation for the gene encoding α-IPMS)
exhibits variable-number tandem repeats (VNTR) of a 57-nucleotide sequence,
naturally present between two and twenty-one times21 (MtuIPMS strain H37Ra
used in this study has two repeats). Deletion of this sequence has no significant
effect on catalysis.22
A large body of work is based on M. tuberculosis α-IPMS (MtuIPMS) due to
its desirability as a drug target, and as until recently this was the only α-IPMS
with a full-length crystal structure available.
1.3.1 MtuIPMS Structure
Full length crystal structures have been found for MtuIPMS9 and L. biflexa
α-IPMS (short form, leuA2 ).23 The L. biflexa enzyme lacks a regulatory do-
main, and will be discussed later. The MtuIPMS structure is composed of an
asymmetric homodimer, depicted in Figure 1.3.
Catalytic Domain
The catalytic domain is a dimer of (β/α)8 barrels. Subdomain I wraps around
to cap the active site of the other chain with an α-helix, contributing necessary
residues for catalysis. A short linker connects subdomains I and II, the latter
being a trio of α-helices, which support the dimerised (βββα)2 regulatory do-
main. Leucine can be found (PDB: 3FIG) bound to each half of the dimer,
near the dimer interface, as shown in Figure 1.4. When leucine is absent, the
structure is practically identical (aligning Cα atoms in 1SR9 and 3FIG - leucine
absent and bound, respectively - gives RMS = 0.23 Å).
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Active Site & Subdomain I
The active site is located at the C-terminal end of each catalytic barrel. The
residues Asp-81, His285, and His-287 bind a divalent metal ion (i.e. Zn2+),
responsible for orientating α-KIV by coordinating the two carbonyl groups, and
activating the α-carbonyl for nucleophilic attack. α-KIV is further stabilised by
hydrogen bonds to Arg-80 and Thr-254. These details are shown in Figure 1.5.
Subdomain II
Subdomain II looks like a hinge, and occupies quite a different orientation with
respect to the catalytic domain in each chain (see Figure 1.6). The reason
for this asymmetry is unclear. It appears to play a role in conducting the
allosteric signal from the regulatory domain to the active site.24 Truncations
that disrupt subdomain II inactivate the enzyme,23,25 and it has been argued23
that subdomain II may play a crucial role in coordinating AcCoA for catalysis.
This is supported by the findings of Zhang et al.23 that partially truncating
L. biflexa α-IPMS (short form) to disrupt subdomain II does not affect α-
ketobutryate binding, but doubles the Km for AcCoA and drastically lowers
the catalytic rate.
Regulatory Domain
It has been shown that the regulatory domain is not required for catalysis,23
but it is the site where leucine binds to effect allosteric regulation. This was
depicted in Figure 1.4, and will be discussed further in the next chapter.
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Figure 1.3: MtuIPMS crystal structure (PDB ID: 3FIG). Chain A is in grey,
chain B is coloured according to domain. Zn2+ ion shown in the active site
of chain B as a red sphere. Some flexible loops are not shown due to missing
electron density.
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Figure 1.4: MtuIPMS crystal structure (PDB ID: 3FIG) showing close-up of
the regulatory domain. Bound leucine molecules are shown in pink.
Figure 1.5: MtuIPMS active site. Zn2+ depicted as a sphere. Note the
contribution of His379 and Tyr410 from the other chain, via subunit I (grey).
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Figure 1.6: Subdomain II appears to act as a hinge between the catalytic
barrel and the regulatory domain. The view from each side of the enzyme is
shown here to demonstrate the asymmetrical arrangement of subdomain II and
the regulatory domain with respect to the catalytic domain. Missing electron
density from flexible loops is more obvious here than in Figure 1.3.
CHAPTER 1. INTRODUCTION 11
1.3.2 LbIPMS
The crystal structures (PDB ID: 4OV4, 4OV9) of LbIPMS align closely with
that of MtuIPMS, as shown in Figure 1.7. The obvious exception is subdo-
main II: as LbIPMS lacks the constraints of the MtuIPMS regulatory dimer,
subdomains II adopt a different conformation. They are still asymmetrically
positioned, just as in MtuIPMS. The similarity between the structures reinforces
the generalisations about α-IPMS we have drawn from MtuIPMS.
1.3.3 Catalysis
MtuIPMS is a metalloenzyme, catalysing a Claisen condensation between α-
KIV and AcCoA under slightly basic conditions. While a divalent metal ion is
required for catalysis, frequently monovalent cations (i.e. K+, Na+, and NH4
+)
are activating in several α-IPMS enzymes.26–28 As these don’t appear in any
crystal structures, we are unable to determine their role. They may play a role
in recruiting the divalent metal to the active site.27
De Carvalho et al.27 reported Km values for α-KIV and AcCoA of 12 and
136 mM respectively, with a turnover rate of 3.5 s−1. A comparison with various
other α-IPMS enzymes is shown in Table 1.1. MtuIPMS has been shown to be
able to catalyse AcCoA hydrolysis without α-KIV present. The Km is similar
(160 µM) but with negligible turnover (0.03 s−1).
MtuIPMS has been shown to be somewhat promiscuous with respect to
α-keto acids. For instance, it is able to use pyruvate, α-KB, α-ketovalerate,
α-ketoisocaproate, and α-ketocaproate (shown in Figure 1.8).29,30 Not surpris-
ingly, some orthologs are inhibited by α-ketoisocaproate31 and α-ketovalerate30
and similar structures, presumably due to competitively binding to the active
site.
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Figure 1.7: Overlay of LbIPMS (4OV4) with MtuIPMS (3FIG). Catalytic
domains align with RMS = 1.71 Å. MtuIPMS is shown in sky blue, with
subdomain II in dark blue. LbIPMS is shown in grey, with subdomain II in
darker grey. Active site molecules depicted as orange spheres.
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Mechanism
The mechanism proposed by De Carvalho et al.31 is shown in Figure 1.9.
A divalent metal ion coordinates the carbonyl groups of α-KIV, activating
the α-carbonyl for nucleophilic attack. A basic residue abstracts a proton
from the terminal methyl group of AcCoA, which attacks the carbonyl by a
concerted mechanism. A second base abstracts a proton from water, providing
a nucleophile to hydrolyse AcCoA, releasing CoA and α-isopropylmalate.
Table 1.1: Comparison of basic kinetic parameters for several α-IPMS enzymes.
Not all studies reported a kcat value.
Organism Km α-KIV (µM) Km AcCoA (µM) kcat (s
−1)
M. tuberculosis 27 12 136 3.5
Neisseria meningitidis 32 30 35 13
Arabidopsis thaliana*30 304 45 2.4
N. crassa 26 10 25 –
S. cerevisiae 28 16 9 –
Salmonella typhimurium 33 60 200 –
* Isozyme 1
Figure 1.8: Some alternative substrates for MtuIPMS.
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Figure 1.9: Mechanism adapted from De Carvalho et al.31 B1 and B2 are
unidentified basic residues, and H-A an acidic residue in the active site. A
generalised α-keto acid is shown here rather than α-KIV.
1.3.4 Regulation
α-IPMS is allosterically feedback-regulated by L-leucine, but the mechanism by
which the allosteric signal is propagated approximately 50 Å from allosteric to
catalytic site is not fully understood. Our understanding of allostery has gradu-
ally evolved since the 1960’s, when the theories of Monod et al.34 and Koshland
et al.35 were first proposed. Each theory suggested that enzymes could exist in
one of two states, a “relaxed” state: able to bind substrate and conduct catalysis;
and a “tense” state (caused by inhibitor binding), that prevents substrate
binding and catalysis. While these theories provide a reasonable explanation
of the gross conformational shifts seen in some systems, it is now recognised
that enzymes are necessarily dynamic, flexible systems. Rather than two rigid
conformations, enzymes occupy a range or “ensemble” of conformations that
shift according to physical and chemical conditions. Upon binding an allosteric
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effector, the ensemble shifts to a different range of conformations, which results
in activation or inhibition of catalysis.36,37
As leucine binding has almost no effect on the crystal structure of MtuIPMS,
implying the nature of allosteric regulation must be through altered enzyme
dynamics, rather than gross changes in structure. Frantom et al.24 probed
the allosteric network in MtuIPMS by amide hydrogen/deuterium Exchange
(HDX) experiments. Enzyme was incubated in D2O before being subjected
to proteolysis and mass spectroscopy. Experimental conditions could then be
altered, and changes in deuterium uptake would reflect any change in solvent
exposure or protection certain regions of the protein experienced.
As would be expected, several peptide fragments originating near the allo-
steric site showed a decrease in deuteration upon leucine binding (see Figure 1.10).
However, one fragment (residues 78-87) from the catalytic site also showed
decreased deuteration: this region includes several conserved residues, including
Arg-80, which helps stabilise α-KIV. The same fragment showed decreased
deuteration in the enzyme mutant Y410F.
As can be seen in Figure 1.5, Tyr410 is present on a loop in subdomain I,
and is thought to orientate His379 for catalysis.9 Tyr410 is, in turn, orientated
by hydrogen bonds from its phenolic moiety to Gln176 and Glu218. Mutating
to phenylalanine disrupts these contacts, and severely compromises catalysis.
The catalytic rate of this mutant is similar to the fully inhibited wild-type,
suggesting this mutation mimics the inhibited wild-type enzyme. While this
gives us clues as to the proximal mechanism of inhibition, it reveals little about
the transmission of the allosteric signal to the active site.
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Figure 1.10: HDX experiments show areas of decreased solvent exposure in
MtuIPMS upon leucine binding (regions shaded blue). Leucine is shown bound
in the allosteric site (green).
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1.4 Citramalate Synthase
Citramalate synthase (CMS) (EC 2.3.1.182) is the first step in an alternative
pathway for producing α-KB from pyruvate rather than threonine. It has only
been characterised in a handful of organisms.38–43 To date, Swiss-Prot lists only
13 other CMS sequences.44
CMS catalyses the first step in the citramalate pathway shown in Figure 1.2,
the Claisen-condensation of two pyruvate molecules to form (R)-citramalate.
It is feedback-regulated by isoleucine. Available kinetic parameters are sum-
marised in Table 1.2.
Table 1.2: Kinetic parameters available for CMS enzymes.
Organism Km pyruvate (µM) Km AcCoA (µM) kcat (s
−1)
L. interrogans 60 1100 10
Methanococcus jannaschii 180 303 0.36
Rhodospirillum rubrum – 3200 –
Partial crystal structures exist for L. interrogans CMS (LiCMS) (PDB
ID: 3F6G - regulatory domain, 3BLI - catalytic domain).15 L. interrogans
is the causative agent in “rat-catcher’s fever”, a zoonotic infection primarily
contracted by contact with soil or water contaminated with animal urine. The
crystal structures align well with the leuA structure, as seen in Figure 1.11, with
RMS = 2.5 Å (regulatory domains) and 1.7 Å (catalytic domains). Isoleucine is
bound in the same pocket that binds leucine in MtuIPMS (show in Figure 1.12).
While no structures exist of MtuIPMS with AcCoA bound, it is present in
LiCMS (PDB ID: 3BLI). This is shown in Figure 1.13.
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Figure 1.11: Partial crystal structures of LiCMS (blue) aligned to MtuIPMS
(grey) with RMS ≤ 2.5Å. PDB IDs: 3F6G (regulatory domain) and 3BLI
(catalytic domain).
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Figure 1.12: Isoleucine-binding pocket with isoleucine bound (lighter blue).
PDB ID: 3F6G.
Figure 1.13: AcCoA binding in LiCMS (blue), pyruvate (yellow), and Zn2+
(purple). Overlaid is MtuIPMS (grey), indicating where AcCoA may bind in
that enzyme. PDB ID: 3BLI.
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1.5 Thesis Objective
The objective of this thesis was to explore the selectivity and underlying mech-
anism of allostery in α-IPMS enzymes. One aim was to investigate the residues
binding the allosteric effector in MtuIPMS, and gain a better understanding of
how they cooperate to mediate effector recognition. The other main aim was to
investigate some of the residues highlighted by molecular dynamics simulations,
and determine whether they play a role in transmitting the allosteric signal from
the regulatory domain to the catalytic domain.
The enzymes used in this study, MtuIPMS and NmeIPMS were chosen as
they were already reasonably well-characterised in our lab, and in the literature.
Enzymes from these organisms are of general scientific interest due to the
pathogenicity of their host organisms, and by pursuing a range of different









MtuIPMS is allosterically inhibited by leucine, but not significantly by chemical
analogues such as isoleucine. The goal of this project was to mutate the allosteric
site of MtuIPMS so that it would bind and be inhibited by isoleucine or similar
amino acids.
21
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Using insights from X-ray crystallography and building on previous work
by Tyler Clarke,1 multiple-point site-directed mutagenesis (SDM) was used to
create several candidate enzymes for analysis.
The enzymes were expressed and purified. A circular dichroism (CD) spec-
trum was obtained for each enzyme and compared with the wild-type to the
secondary structure. Differential scanning fluorimetry (DSF) was trialled as a
first-pass screen for inhibitory activity of various amino acids. Finally, enzyme
inhibition studies were carried out to test whether the allosteric specificity of
MtuIPMS had changed as expected.
2.2 Background
MtuIPMS and LiCMS catalyse a very similar reaction: an aldol reaction be-
tween AcCoA and a small α-keto acid. Although they show only around 34%
sequence similaritya, crystal structure overlays show a high degree of similarity.
The crystal structure of MtuIPMS (PDB ID: 3FIG) aligns to the crystal struc-
tures of LiCMS with a RMS of 1.95 Å for catalytic domain (PDB ID: 3BLE)
Cα atoms, and 3.03 Å for regulatory domain Cα atoms (PDB ID: 3F6G). The
resolution of these structures were 2.30 Å, 2.00 Å, and 2.00 Å respectively.
MtuIPMS and LiCMS are both allosterically inhibited by the end-products of
their metabolic pathways, leucine and isoleucine respectively.
In the characterisation of LiCMS by Zhang et al.,15 it was found that a
single mutation (V468A) was sufficient to result in allosteric inhibition with
leucine. Interestingly, this mutant was twice as sensitive to isoleucine as the
wild-type enzyme, but it had gained some measure of leucine sensitivity, as can
be seen from the IC50 values displayed in Table 2.1.
aPairwise alignment from www.ebi.ac.uk using a BLOSUM62 matrix
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Table 2.1: Inhibition values for LiCMS V468A, adapted from Zhang et al.15
LiCMS IC50 Ile IC50 Leu
wild-type 86 ± 20 —
V468A 41 ± 8 343 ± 41
Attempting to produce the reciprocal result in MtuIPMS, Clarke1 identified
four residues thought to be key for leucine binding in MtuIPMS. These residues,
Val551, Ala558, Ala567, and Ile627 were mutated to their corresponding CMS
residues and the resultant enzymes were characterised. Interestingly, none
of these mutations introduced any sensitivity to isoleucine, but A558I and
I627A each showed a marked reduction in leucine sensitivity. A567V (the
mutation corresponding to LiCMS V468A) was still sensitive towards leucine,
but showed an increased sensitivity towards norvaline. This project tests a
rational combination of these mutations to see whether MtuIPMS can be made
sensitive to isoleucine by a combination of two or more mutations.
2.3 Residues Important for Allostery
Table 2.2: Distances between nearest points of allosteric site residues and






Val-551 4.3 Leu-451 4.4
Ala-558 4.1 Ile-458 4.1
Ala-567 4.0 Val-468 3.8
Ile-627 3.8 Gln-495 3.6
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Figure 2.1: Overlay of allosteric sites of MtuIPMS (green) & LiCMS (blue).
Allosteric effector molecules and important residues depicted and labelled.
PDB structures (3FIG & 3F6G, respectively) aligned by Cα positions. Some
representative distances are shown.
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Figure 2.2: MSA of allosteric binding site residues in α-IPMS and CMS
Enzymes. MSA constructed using Jalview/ClustalO45,46
A close examination of the crystal structure of MtuIPMS overlaid with
the allosteric domain of LiCMS reveals interesting details about the allosteric
binding site of these enzymes (Figure 2.1). Table 2.2 lists the main residues
thought to be responsible for allosteric effector binding from MtuIPMS and
LiCMS. The multiple sequence alignment (MSA) in Figure 2.2 shows these
residues are reasonably well-conserved across various α-IPMS enzymes.
The lack of absolute conservation implies that either than absolute speci-
ficity is not important, or that the residues involved in mediating allosteric
effector recognition work cooperatively rather than through individual, specific
interactions. For instance, Fox et al. found in a directed evolution experiment
that combinations of mutations lead to a positive outcome that had no effect by
themselves. While none of the mutants tested by Clarke showed any isoleucine
CHAPTER 2. ALTERING ALLOSTERY OF MTUIPMS 26
sensitivity, this may be because a combination of mutations are required to
sufficiently alter the allosteric pocket.
The kinetic assays revealed no significant changes to Km or kcat for any
of the mutants, but the inhibition assays showed some enzymes had lost their
sensitivity to leucine. None of the enzymes were inhibited by isoleucine, but
A567V developed a strong sensitivity towards norvaline, while suffering a small
decrease in sensitivity towards leucine. Presumably the mutant valine sidechain
adds just enough steric bulk to discourage the isopropyl terminus of leucine’s
sidechain, while providing enough extra hydrophobic interactions to make bind-
ing to norvaline’s propyl sidechain more favourable. As isoleucine shares this
unsubstituted propyl group, it may prove to be one of the more important
















+ CH3 + CH3
Shortened backbone
-CH2
Figure 2.3: Amino acids tested as inhibitors in this study. The sidechain of
norvaline is coloured red, and is shown (substituted or truncated) in the other
amino acids, showing the structural similarity explored in this study. *Valine
was not tested in the previous study.
Based on the crystal structure, we would expect I627A to remove the steric
hindrance preventing accommodation of isoleucine’s β-methyl group. The study
found that this mutation also removes inhibition by leucine and norvaline.
Presumably some of the hydrophobic interactions stabilising the binding of
leucine or isoleucine have also been removed. The other two mutants (A558I
and V551L) strongly decrease leucine sensitivity, and weaken that of norvaline.
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Their positions in the crystal structure suggest a role in regulating the amount
of space available for aliphatic sidechains to be accommodated, which would
explain why they reduce sensitivity to leucine, but not necessarily norvaline.
Their role in shaping isoleucine sensitivity will be further explored in this
project.
In preparing for this work, the DSF results obtained by Clarke were carefully
analysed. DSF measures the thermostabilising effect produced when small
molecules bind to a protein,47 and this was used in an attemot to predict the
allosteric properties of the enzymes. Figure 2.4 shows the predictive value of
DSF in the previous study was, at most, rather limited (R2 = 0.246). This is not
entirely surprising as we can only infer that the amino acids are binding at the
allosteric site: they may in fact have some non-specific binding properties. An
example of this possibility would be the use of arginine in the refolding misfolded
proteins,48 (although admittedly at much higher concentrations). We must also
consider that there will be both enthalpic and entropic factors affecting the
binding of ligand molecules and the ability of these to stabilise large, dynamic
systems such as proteins. DSF will be further explored in this study, with a
larger sample size, to explore whether it provides a good indication of allosteric
properties of MtuIPMS.
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Figure 2.4: DSF was a reasonably poor predictor of which amino acids would
be allosteric effectors for previously studied MtuIPMS mutants. Data is shown
for 5 mM concentrations, lower values had a similar effect (data not shown).
DSF was carried out on 25 µL samples containing 160 µg/mL protein in BTP
buffer (pH 8.0).
2.4 Generation of Mutants
As A567V had shown some promise in opening up the allosteric profile of
MtuIPMS it was treated as a “base” mutation, to which was added various
combinations of the other mutations as delineated in in Table 2.3.
Table 2.3: Table of planned mutations
Mutation Mutant, designated “Mtu-...”
1 2 3 4 5 6 7
A567V X X X X X X X
A558I X X X X
V551L X X X X
I627A X X X X
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The first step was to obtain a pure sample of pProEx-HTa-LeuA plasmid,
containing the MtuIPMS (leuA) gene along with several other features to aid
purification. A T7 promotor is present upstream of the gene to allow induction
of overexpression with isopropyl β-d-1-thiogalactopyranoside (IPTG). An N-
terminal (His)6-tag simplifies purification, and a tobacco etch virus (TEV)
protease recognition site allows tag removal. A gene encoding for ampicillin-
resistance acts as a selection marker. A small overnight culture of bacteria
carrying the plasmid was processed using a commercially available plasmid-
extraction kit to obtain a sample of the plasmid. This was checked by agarose
gel electrophoresis for size and purity, as shown in Figure 2.5.
Figure 2.5: Purified plasmid, with supercoiled, linear, and nicked forms clearly
seen.
As the project required multiple steps of SDM to produce the required
mutants, obtaining pure template DNA was crucial for effective SDM reactions.
Initial SDM attempts were repeated many times, varying a wide variety of
conditions: but consistently failed. This was eventually blamed on cellular
RNA co-purifying with and contaminating the extracted plasmidb. The RNA
had initially been missed, due to longer electrophoresis running times leading
to the RNA running off the gel. The presence of RNA would significantly
bAnnette Stewart, personal communication, August 2014
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inflate the nucleic acid concentration estimated by OD260, leading to insufficient
template being used in the SDM reactions. Changing plasmid-extraction kit
suppliers resulted in much purer plasmid extracts (no RNA visible on agarose
gels), which allowed further SDM to proceed smoothly. SDM products were
digested with DpnI restriction enzyme to remove methylated (template) DNA,
leaving the newly synthesised, unmethylated mutant DNA intact. This was used
to transform chemically competent E. coli cells, which were grown overnight and
several colonies picked for plasmid extraction. Extracted plasmids were typically
subjected to PCR using pProEx sequencing primers, and both plasmids and
PCR products analysed by agarose gel electrophoresis to ensure correct size
(see Figure 2.6). Plasmids were submitted for DNA sequencing analysis to
confirm the mutation and integrity of the gene. A sample of a plasmid with
the correctly mutated sequence was used to transform chemically competent E.
coli expression strain cells, which were stored as glycerol stocks at -80°C until
required for growth and protein expression.
Figure 2.6: Checking mutant plasmids and their PCR products.
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2.5 Protein Expression and Purification
Wild-type and mutant MtuIPMS enzymes were grown and expressed as per the
methods described in Section 5.4. The various stages of purification can be seen
on SDS-PAGE gels in Figure 2.7. The following sections outline this process.
(a) HisTrap (b) Size-Exclusion Chromatography
Figure 2.7: Mtu-7 purification visualised by SDS-PAGE.
2.5.1 Protein Extraction
Fresh or thawed cell pellets were resuspended and lysed by sonication on ice with
Benzonase® Nuclease (Sigma) to break down nucleic acids. Lysate was clarified
by centrifugation and filtration, and the insoluble pellet resuspended in 8 M urea
for electrophoresis. The lysate and soluble fractions in Figure 2.7a show clear
overexpression of the tagged MtuIPMS enzyme at 73 kDa, but the insoluble
fraction still contains a certain amount of protein, suggesting incomplete lysis.
2.5.2 Immobilised Metal Affinity Chromatography (IMAC)
The clarified soluble fraction was loaded onto a HisTrap (GE Healthcare) IMAC
column. These columns coordinate Ni2+ ions, but leave several coordination
CHAPTER 2. ALTERING ALLOSTERY OF MTUIPMS 32
sites free. These sites are bound by imidazole moieties on polyhistidine tags
(His-tags), causing highly specific binding of tagged proteins to the column. An
imidazole gradient is used to elute the protein, which is monitored by absorption
at 280 nm. The protein elutes reasonably pure, as can be seen in the pooled
fractions, gelled in the final lane of Figure 2.7a. A desalting column was then
used to remove the imidazole, to prevent it interfering with the following step.
2.5.3 TEV Protease Treatment
To remove any interference in enzyme function from the His-tag, the tag was
cleaved by TEV protease at a recognition sequence designed into the short linker
between the polyhistidine section and the beginning of the MtuIPMS sequence.
This sequence is described in Figure 2.8.
MHHHHHHGKPIPNPLLGLDSTENLYFQGA
Figure 2.8: The hexahistidine section (red) binds to the IMAC column, followed
by a linker region (orange), and a TEV protease recognition site (underlined).
The GA residues (blue) after the recognition site remain attached to the protein.
Approximately 1 mg TEV protease was added per 10-100 mg tagged protein,
along with DTT and EDTA. A brief (<60 mins) benchtop incubation step
was followed by overnight incubation at 4°C. The sample was desalted again
to remove the DTT and EDTA, before being subjected to a second IMAC
step. This bound the His-tagged TEV protease enzyme and the cleaved His-tag,
allowing the cleaved protein to elute.
2.5.4 Size-Exclusion Chromatography (SEC)
A final polishing step was carried out via SEC. The enzyme eluted as a single
peak, and fractions were examined by SDS-PAGE (Figure 2.7b). The mass
inferred from the gel (≈ 70 kDa) matches the predicted protein size. All fractions
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visually judged to be >95% pure were pooled and concentrated to >1 mg/mL,
and flash-frozen in liquid nitrogen before being stored at -80°C.
2.6 Physical Characterisation
2.6.1 Mass Spectrometry
Mass spectrometry proved difficult for many of the samples prepared in this
report, despite cleaning up samples on an analytical SEC column and repeated
desalting. Keratin contamination was suspectedc. Even with samples carefully
preparing in a HEPA-filtered laminar flow cabinet, contamination was still
present. Mtu-2 and Mtu-3 had their mass measured successfully within 1 Da
of the predicted value. For the other mutants, full-length DNA sequences
were obtained of the mutant genes to ensure no other mutations had been
inadvertantly introduced.
2.6.2 Secondary Structure
CD spectroscopy was used to ensure that the mutations had not introduced
any major changes to the fold of the enzymes. Figure 2.9 shows that all of the
mutants adopt similar secondary structure profile to the wild-type, implying
similar folding.
2.6.3 Thermal Stability
A thermal melting curve was obtained by DSF for MtuIPMS wild-type, as shown
in Figure 2.10. The steepest point of the fluorescence curve was found where
the second differential equalled zero (corresponding to the local maximum of the
first differential). The temperature at this point was taken to be the melting
cDr. Alexander Goroncy, Personal communication
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Figure 2.9: CD spectra of MtuIPMS wild-type and mutant enzymes.
(unfolding) temperature of the protein. Readings were taken in triplicate and
averaged. Figure 2.10 shows the fluorescence curve, readings from a control well
with no protein, and the first differential. The second differential was omitted
here for clarity.
As seen in Figure 2.4, DSF seems to be a relatively poor predictor of whether
a given amino acid will inhibit MtuIPMS mutants, at least under the conditions
previously employed. To explore this area more fully, MtuIPMS wild-type and
several of the mutants from this study were probed using a range of amino acid
concentrations. We also expanded the range of amino acids tested to include
valine, so as to more fully explore this chemical space (see Figure 2.3).
MtuIPMS wild-type and Mtu-1, 2, 3, and 5 were subjected to DSF to
determine their melting point. As can be seen in Figure 2.11, these mutants had
melting temperatures roughly 0.2°C to 1.2°C higher than the wild-type under
than these conditions. This slight gain in stability was consistent with the range
of melting temperatures observed in the previous study’s mutants.
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Figure 2.10: Thermal melt curve of MtuIPMS wild-type. First differential curve
and control wells shown.
Figure 2.11: MtuIPMS mutant enzyme melting temperatures
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As well as the 5 mM concentrations of amino acids used in the previous study,
a more physiologically realistic 0.5 mM concentration was also tested. The
stabilisation of each enzyme with potential inhibitors can be seen in Figure 2.12.
Based on the stabilisation data, we could make several predictions about
allosteric sensitivity, as displayed in Table 2.4.
Table 2.4: Predictions of allosteric sensitivity based on DSF data
Mtu-
Amino acid WT 1 2 3 5
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Figure 2.12: Stabilisation observed with MtuIPMS enzymes in the presence of
varying concentrations of amino acids.
CHAPTER 2. ALTERING ALLOSTERY OF MTUIPMS 38
2.7 Kinetic Characterisation
Due to time constraints Km and kcat values have not yet been measured for
the mutants in this study. However, preliminary kinetic inhibition studies are
presented here.
As can be seen from Figure 2.13 by adding in more mutations to our base
A567V mutation, we can dramatically alter the allosteric sensitivity of MtuIPMS.
Particularly satisfactory is the observation that Mtu-4 (only two mutations
away from the wild-type) is, at every concentration tested, significantly more
inhibited by isoleucine than leucine. We have achieved one of the principle goals
of this project: to switch the allosteric sensitivity of MtuIPMS from leucine
to isoleucine. Of further interest is Mtu-2 (again, two mutations away from
the wild-type), which retains similar sensitivity to leucine as the wild-type,
but is now just as sensitive to norvaline, and nearly as sensitive to isoleucine.
We appear to have created a much more allosterically promiscuous enzyme.
Another mutant worth noting is Mtu-6 (three mutations from the wild-type),
which shows a similar inhibition pattern to Mtu-2, but is comparatively more
sensitive to isoleucine than valine.
2.7.1 Correlation with DSF Predictions
Figure 2.14 shows that melting temperatures and inhibition rates are moderately
well correlated, for both 0.5 mM and 5.0 mM concentrations. Data shown are
for the mutants subjected to DSF in this study, and the mutants from the
previous study. DSF was not carried out on several mutants (Mtu-4, -6, & -7)
as despite the correlation, individual results can be seen to be highly unreliable
in predicting allosteric activity. For instance, according to the figure, a gain of
2°C melting temperature could correspond to anywhere between 8% and 95%
reduction in activity. Table 2.5 summarises the success of predictions made from
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Figure 2.13: Inhibition of MtuIPMS enzymes by different amino acids, at
concentrations ranging from 0mM to 5mM. Activities were measured in 250µM
α-KIV and 425µM AcCoA. The Km values for the wild-type enzyme are 12 µM
and 136 µM respectively. The concentration of AcCoA is not quite saturating,
due to the high Km for this substrate.
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Table 2.5: Testing DSF predictions of allostery. DSF proved a reasonable,
although not entirely reliable guide to allosteric activity.
Mtu-
Amino acid WT 1 2 3 5
Leucine !! ∼ ! # !!
Isoleucine ∼ # ! !! !!
Norvaline ! # ! !! !
Valine # # ! ! !
!!: DSF correctly predicted the degree of inhibition.
!: predicted whether or not there was inhibition.
∼: no inhibition predicted, only weak inhibition observed.
#: activation or no inhibition predicted, moderately strong inhibition observed.
Figure 2.14: Using the data from several mutants in this study, and the previous
study, DSF does show moderate predictive power for inhibition.
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the DSF results in this study. As can be seen from the table, the predictive
success of DSF was rather mixed, so we chose not to characterise the remaining
mutants by DSF, opting to focus on kinetic studies.
2.8 Summary
Seven new variants of MtuIPMS were created, purified, and characterised by
DSF and kinetic inhibition studies. While DSF is often cited as a good first-
pass approximation for protein-ligand binding, our study suggests that, at least
for MtuIPMS, this isn’t a reliable screening tool. While there is a good overall
predictive value for DSF results, if we had chosen which mutants to kinetically
characterise based purely on DSF, we would have missed many interesting
allosteric interactions.
The goal of this project was to switch the allosteric specificity from leucine to
isoleucine, and in the case of Mtu-4, this was a success. At every concentration
tested, isoleucine was a significantly better inhibitor than leucine. Based on
the crystal structure, Ile627 was the major barrier to isoleucine binding, as
it sterically blocked the β-methyl group of its sidechain. Ile627 also seems to
provide favourable hydrophobic interactions with the β-carbon of leucine and
norvaline. Ala567 seems to stabilise the terminal isopropyl group of leucine,
while valine in this position does a better job of stabilising isoleucine’s terminal
methyl carbon. The valine mutants would also restrict the space available for
leucine’s isopropyl terminus. Mutating Ile627 to alanine was not enough to allow
isoleucine to bind by itself, but with A567V it seems we have better provided the
hydrophobic interactions needed to stabilise isoleucine, while tuning the steric
factors to disfavour leucine binding.
Mtu-2 and Mtu-6 have both become rather allosterically promiscuous com-
pared to the wild-type with the addition of V551L. This is the most conservative
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mutation explored here, both structurally and sequence-wise: Figure 2.2 shows
that these two residues are commonly interchanged among α-IPMS enzymes.
The extra methylene in leucine gives the sidechain more flexibility, which could
explain why it allows the allosteric pocket to accommodate a wider range of
inhibitors.
A558I seems to be an awkward mutation in MtuIPMS. It consistently lowers
the allosteric sensitivity for all molecules whenever it is present, and Clarke
showed it lowers the melting point of wild-type MtuIPMS. PyMOL modelling
suggests the least sterically hindered conformation it can adopt places the ethyl
group of its sidechain in a polar environment, as can be seen in Figure 2.15. We
would predict that this would both lower the stability (explaining the lowered
melting point) and project a methyl group into the allosteric pocket, reducing
the ability of our inhibitors to bind.
We expected that Mtu-7, carrying all of the mutations identified from CMS,
should be the best at binding isoleucine: but in fact it shows a fairly poor
inhibitory profile. This could be due to the destabilising effect of A558I, and
indeed Mtu-6 (which carries the other three mutations) does have the strongest
response to isoleucine. However, as discussed above, V551L seems to allow
greater promiscuity, so even though Mtu-4 shows slightly less sensitivity to
isoleucine than Mtu-6 does, it is more selective for isoleucine.
Exploring the role of A558I by crystallography would be worthwhile, to
confirm our speculations as to how it is affecting the allosteric site. It would be
interesting to crystallise some of the other enzymes in this study with various
inhibitors bound, to study the exact nature of the changes we have made. Now
that we have caused some interesting changes to the allosteric properties, it
would be worthwhile to construct mutants without A567V, to see whether this
mutation is, in fact, critical for isoleucine sensitivity.
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Figure 2.15: A558I reduces inhibition and stability of the enzyme. The ethyl
group is forced into a polar pocket of carbonyl and hydroxy groups, while the
upwards-protruting methyl group sterically hinders inhibitor binding. PyMOL








In the previous chapter we used insights gleaned from the crystal structure
of MtuIPMS to successfully make rational mutations, altering its allosteric
specificity. Neisseria meningitidis α-IPMS (NmeIPMS) is a smaller protein
(∼56 kDa vs ∼70 kDa) and has fewer decorations (for instance, MtuIPMS has
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variable numbers of tandem repeats22 and an N-terminal extension9 absent in
NmeIPMS). Due to these considerations, and as there is no complete crystal
structure for NmeIPMS, Dr. Wanting Jiao has constructed a homology model
for molecular dynamics (MD) simulations. Both enzymes are feedback inhibited
by L-leucine through altered molecular dynamics rather than alterations to the
tertiary or quaternary structure.9,24,25,49 This work tests in vitro the predictions
made by MD simulations in silico, in order to shed light on the mechanism by
which the signal is conducted from the allosteric pocket to the active site.
The asymmetric, domain-swapped nature of the α-IPMS dimer, first de-
scribed in MtuIPMS (PDB ID: 1SR9 etc.) is preserved in the homology model
of NmeIPMS. The catalytic barrel of one chain is capped by subdomain I of
the other chain, and positioned adjacent to subdomain II and the regulatory
domain of that second chain. The active site on one side of the dimer is
relatively open, while subdomain II and the regulatory domain sit much closer
to the catalytic site on the other side. Figure 3.1 shows the overall structure
of the model and Figure 3.2 shows the domain-swapped nature of the dimer.
The asymmetry of the dimer is curious: what, if any, functional purpose does
the asymmetry serve? It is unclear whether the active site is catalytically
active in both the “open” and “closed” conformations, or whether only one
catalytic site per dimer is active. In which case, is the other chain merely a
complicated structural prop? Or perhaps the protein undergoes a pendulum-like
rearrangement, with the regulatory domain flopping back and forth, allowing
both sites to catalyse reactions. This may play a role in allostery, or perhaps
in substrate binding and product release. Similar questions are considered in
several systems in a review by Nagradova.50 So far, solution-phase studies and
mutagenesis on MtuIPMS51 have revealed few clues, and initial MD simulations
indicate a prohibitive energetic barrier to any such rearrangementsa. However,
aPersonal communications, Dr. Wanting Jiao
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that leaves unexplained the reason for the asymmetry. Domain movement in α-
IPMS enzymes will be briefly examined in the experiments here, which promises
some interesting preliminary results.
Several residues of interest were identified by Dr. Jiao for experimentation.
These were mutated and the corresponding proteins purified for analysis. Mass
spectra were obtained for most of the enzymes and were in good agreement
with the predicted mass. The secondary structure was investigated by circular
dichroism (CD) spectroscopy, and no evidence of misfolding was found. Pre-
liminary kinetics testing has been carried out and the results warrant further
investigation.
3.2 Residues Selected for Analysis
The following residues were identified by Dr. Jiao for experimental analysis.
This information is summarised in Table 3.1.
3.2.1 Tyr313
Studies have identified Tyr410 as a key residue mediating allostery in MtuIPMS.24,29
Multiple sequence alignments (MSA) show this is strongly conserved, and cor-
responds to Tyr313 in NmeIPMS (Figure 3.3). In MtuIPMS, Koon et al.9
identified Tyr410 as being responsible for orientating the catalyticaly important
His379 residue. Substituting phenylalanine for tyrosine at this position has been
shown to completely eliminate inhibition by leucine.29 While leucine binding
seems to be unaffected, H/D exchange experiments24 show residues near the
active site adopt similar dynamics (and catalytic rate) to the inhibited enzyme,
regardless of whether leucine is present. As this tyrosine residue seems to be so
well conserved, we would expect the same effect should be present in NmeIPMS.
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Figure 3.1: Rendering of the NmeIPMS homology model. Catalytic domain
shown in red, subdomain I in orange, linker in yellow, subdomain II in green,
and the regulatory domain in blue. The asymmetrical arrangement of the
homodimer is clearly visible. On the left side, as shown here, the end of
the catalytic barrel (Zn shown in pink to denote the active site) is relatively
uncovered, whereas on the right, it is somewhat covered by subdomain II and
the regulatory domain. We will refer to these as the “open” and “closed”
conformations, respectively.
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Figure 3.2: NmeIPMS homology model, chain B coloured grey. The domain-
swapped nature of the enzyme can be clearly seen: subdomains I, II, and the
regulatory domain of chain B are all on the same side as the catalytic barrel of
chain A, and vice versa.
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As a key catalytic residue, substitution with alanine ought to drastically lower
the catalytic rate.
3.2.2 Arg32 & Asp375
On one side of the asymmetric dimer, Arg32 and Asp375 appear to form a salt
bridge (Figure 3.4), stabilising the asymmetric conformation we see from the
MtuIPMS crystal structures, with one chain in the “closed” conformation and
the other “open”. MD simulationsb indicate that when leucine binds to the
regulatory domain, the dimer forms a more rigid, symmetrical conformation.
By mutating either Arg32 or Asp375 to cysteine, we should be able to disrupt
the salt-bridge and see whether it mimics the effect of leucine binding, or
uncouples leucine binding from catalysis. It may even increase the catalytic rate,
if rearrangement between asymmetric conformations is required for catalysis.
If both residues are mutated to cysteine, we would predict that a disulfide
bridge would form between them, preventing any pendulum-like rearrangement
of the “open” and “closed” conformations, and disallowing any intermediate
symmetrical states. If the enzyme does indeed undergo rearrangement as part
of allostery or catalysis, fixing it in one conformation should drastically alter its
kinetic behaviour. Previous work by Dr. Frances Huisman52 achieved a similar
disulfide-forming mutant in MtuIPMS, and found a substantial reduction in
activity. However, it was shown that one of the mutations by itself was sufficient
to provoke this reduction in activity, and so it was not clear whether the disulfide
bridge had any effect. In this work, both single cysteine mutations in NmeIPMS
(R32C and D375C) are isolated and assayed. If these mutants do not alter
catalytis significantly, it would be sensible to construct the double-mutant and
see whether it forms a disulfide bridge. If it does, any change in catalysis or
regulation must be due to the restriction of domain movements. This would
bDr. Wanting Jiao, unpublished work
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(a) Tyr410 is seen to be highly conserved in this MSA constructed
using Jalview/ClustalO.45,46
(b) Active site of NmeIPMS from homology model. Y313 is predicted to have polar contacts
with several nearby residues. Catalytic zinc ion and α-KIV are shown to denote the active
site. Catalytic domain is coloured in red, subdomain I in orange, and the linker in yellow.
Figure 3.3: MtuIPMS Y410 is a strongly conserved residue, and has been
implicated in mediating the allosteric signal. The corresponding residue in
NmeIPMS is Y313.
CHAPTER 3. MOLECULAR DYNAMICS OF NMEIPMS 51
provide insight into the role of any pendulum-like rearrangements in allostery
or catalysis in α-IPMS enzymes.
Figure 3.4: Homology model of NmeIPMS. By disrupting the salt-bridge formed
by Arg32 and Asp375, or locking it into a disulfide bridge, we hope to learn more
about the role of flexibility between the regulatory and catalytic domains in α-
IPMS enzymes.
3.2.3 Lys332
In the leucine-bound MD simulation, subdomain I is lifted slightly out of the
catalytic site: this may be how the catalytic rate is reduced in the inhibited
enzyme. Lys332 is part of the linker between subdomains I and II, and forms
polar interactions with Glu18 and Asp56 (see Figure 3.5) on the catalytic barrel.
This seems to restrict the ability of subdomain I to move away from the catalytic
barrel. Mutating Lys332 to alanine may therefore disrupt catalysis or inhibition.
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Figure 3.5: Homology model of NmeIPMS. Lys332 may play a role in mediating
allostery, restricting movement of subdomain I during leucine binding.
3.2.4 Arg470
When leucine binds the allosteric domain, Arg470 on one chain loses a hydrogen
bond to Glu353, and forms one with Glu349 (Figure 3.6). Previous work by
Tyler Clarke1 showed that mutating Glu353 alone is not enough to disrupt
inhibition, but Arg470 looks more promising as a mutagenesis target. By
disrupting this shifting hydrogen bond network we may be able to disrupt
inhibition.
3.3 Generation of Mutants
Site-directed mutagenesis (SDM) proceeded as per the previous chapter. A
commercially available plasmid-extraction kit was used to isolate template DNA
from a small overnight growth of an E. coli plasmid propagation strain con-
CHAPTER 3. MOLECULAR DYNAMICS OF NMEIPMS 53
(a) No leucine.
(b) Leucine bound.
Figure 3.6: Molecular dynamics simulation structures kindly supplied by Dr.
Wanting Jiao. One one chain Arg470 changes hydrogen bonds between Glu353
and Glu349 when leucine binds.
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Table 3.1: NmeIPMS mutants identified for testing.
Residue Mutation Rationale
Y313 F / A Residue corresponding to Tyr410 in MtuIPMS, found to
uncouple leucine binding from inhibition. We would predict
the same effect in NmeIPMS.
R32 / D375 C Form a salt-bridge between the catalyic barrel and subdo-
main II when the enzyme is in its “open” conformation. Dis-
rupting this bond may interupt allosteric signal conduction.
Residues were mutated to cysteine in preparation for the
construction of a double-mutant which may be able to form
a disulfide bond. This would tell us whether alternating
between “open” and “closed” conformations is important
for catalysis and/or regulation.
K332 A May hold subdomain I clear of the catalytic site upon leucine
binding, or prevent it from moving too far away. Destroying
this interaction may remove leucine sensitivity or disrupt
catalysis.
R470 A Forms salt-bridges with two nearby residues: Glu353 when
no leucine is present, and Glu349 upon leucine binding.
Removing these contacts may remove leucine-sensitivity.
taining the plasmid pFH01. This plasmid is a pET-151 vector carrying the
NmeIPMS gene, a T7 promotor to induce overexpression with IPTG, N-terminal
(His)6-tag, TEV-protease recognition site for tag removal, and a gene encoding
for ampicillin-resistance as a selection marker. Plasmid is shown along with a
ladder for size in Figure 3.7a).
The template was subjected to SDM to introduce the desired mutations,
and the SDM reaction product was digested using DpnI restriction enzyme
to remove remaining template DNA. The DpnI digest was transformed into
chemically competent E. coli cells which were grown overnight, and several
colonies picked for plasmid extraction. Plasmids were subjected to PCR with
sequencing primers, and both template and PCR product separated on agarose
to check integrity, similar to that seen in Figure 3.7b. Plasmids were then
submitted for DNA sequencing to confirm the mutation and gene integrity. A
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sequence-confirmed plasmid was then used to innoculate a chemically competent
E. coli growth strain, which was stored as a -80°C glycerol stock, until required




(b) PCR products of NmeIPMS
mutant plasmids checked before
sequencing.
Figure 3.7: DNA in the form of wild-type and mutant plasmids, and their
PCR products, were separated on agarose gel electrophoresis to check plasmid
integrity.
3.4 Protein Expression and Purification
Wild-type and mutant NmeIPMS enzymes were mostly grown and expressed
as per the MtuIPMS enzymes from the previous chapter: full details in 5.4.
However, unacceptable loss of protein often occurred with the NmeIPMS vari-
ants while attempting to cleave the polyhistidine tag. Presumably the nat-
ural N-terminal extension present in MtuIPMS increases the accessibility of
the protease recognition site, allowing much easier removal of the tag. Due
to this problem, the wild-type NmeIPMS was purified in both tagged and
untagged form, while the mutants were purified with tags intact to allow for
easier screening. It was found that the N-terminal tag did have a moderate
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effect on catalysis (Table 3.3) but no discernable effect on inhibition (data not
shown).
(a) HisTrap (b) Size-Exclusion Chromatography
Figure 3.8: NmeIPMS-Y313F purification visualised by SDS-PAGE.
3.4.1 Protein Extraction
Fresh or thawed cell pellets were resuspended and lysed by sonication on ice with
Benzonase® Nuclease (Sigma) to break down nucleic acids. Lysate was clarified
by centrifugation and filtration, and the insoluble pellet resuspended in 8M urea
for electrophoresis. The lysate and soluble fractions in Figure 3.8a show clear
overexpression of the tagged NmeIPMS enzyme at 59 kDa, but the insoluble
fraction still contains a certain amount of protein, suggesting incomplete lysis.
3.4.2 Immobilised Metal Affinity Chromatography (IMAC)
The clarified soluble fraction was loaded onto a HisTrap (GE Healthcare) IMAC
column. These columns coordinate Ni2+ ions, but leave several coordination
sites free. These sites are bound by imidazole moieties on polyhistidine tags
(His-tags), causing highly specific binding of tagged proteins to the column. An
imidazole gradient is used to elute the protein, which is monitored by absorption
at 280nm. The protein elutes reasonably pure, as can be seen in the fractions
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gelled in Figure 3.8a. Fractions containing the bulk of the protein were pooled.
Samples to have their His-tag cleaved were treated on a desalting column to
remove imidazole, before the following step (3.4.3). Proteins purified in their
tagged state were simply concentrated and polished on the SEC column (3.4.4).
3.4.3 TEV Protease Treatment
To remove the polyhistidine tag, the sample was incubated with TEV protease,
which cleaves the amide bond at a recognition sequence designed into the short
linker between the tag and the beginning of the NmeIPMS sequence. This
sequence is described in Figure 3.9.
MHHHHHHGKPIPNPLLGLDSTENLYFQGIPFT
Figure 3.9: The hexahistidine section (red) binds to the IMAC column, followed
by a linker region (orange), and a TEV protease recognition site (underlined).
The GIPFT residues (blue) after the recognition site remain attached to the
protein.
Approximately 1mg TEV protease was added per 10-100mg tagged protein,
along with DTT and EDTA. The sample was incubated for approximately 1
hour on the bench to allow the reaction to proceed, before being incubated
overnight at 4°C. The sample was desalted again to remove the DTT and EDTA,
before being subjected to a second IMAC step. This bound the His-tagged TEV
protease enzyme and the cleaved His-tag, allowing the cleaved protein to elute.
3.4.4 Size-Exclusion Chromatography (SEC)
A final polishing step was carried out via SEC. The enzyme eluted as a single
peak, and fractions were examined by SDS-PAGE (Figure 3.8b). The mass
inferred from the gel (≈ 65 kDa) matches the predicted protein size. All fractions
visually judged to be >95% pure were pooled and concentrated to > 1mg/mL,
and flash-frozen in liquid nitrogen before being stored at -80°C.
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3.5 Physical characterisation
3.5.1 Mass Spectrometry
Mass spectrometry measurements were in good agreement with all predicted
values, as shown in Table 3.2. As with MtuIPMS, some proteins were not able
to be measured (i.e. wild-type: tagged and untagged) but full sequencing was
obtained to ensure correct sequence and gene integrity.
Table 3.2: Mass spectrometry results for NmeIPMS mutants. ND (not
determined) means the mass was not able to be measured.
Mutant Measured Mass (Da) Predicted Mass (Da)
Wild-type ND 59,179








CD spectroscopy was carried out on all samples to ensure the mutations had
not result in any misfolding. As can be seen in Figure 3.10 the mutant proteins
all adopted a similar fold to the wild-type.
3.6 Preliminary Kinetic Characterisation
Due to time constraints and limited substrate availability, only preliminary
kinetic results were obtained. Table 3.3 shows the enzymatic activity of each
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Figure 3.10: CD spectra of NmeIPMS wild-type and mutant enzymes.
enzyme studied in the presence of 250 µM α-KIV and AcCoA, and the results
of inhibitions studies are presented in Figure 3.11.
The untagged wild-type enzyme shows approximately six-fold increased ac-
tivity over the tagged wild-type, indicating the tag does exercise a moderate
effect on catalysis. The rate observed here is consistent with the previously
reported32 kcat of 13.0 ± 0.3 s−1. Further investigations should therefore work
on the untagged protein. All other comparisons in this section will use the
tagged wild-type and mutants to control for any effect of the tag.
As we might expect, Tyr313 seems to be rather important for catalysis.
Substituting it with alanine lowers the catalytic rate by a factor of nearly
700. The more conservative phenylalanine substitution still resulted in a ∼80-
fold reduction in activity, comparable with the ∼30-fold reduction de Carvalho
et al.29 found with MtuIPMS Y410F. However, the cited study found that
in MtuIPMS, the Y410F mutant was insensitive to leucine up to 500 µM,
whereas our NmeIPMS Y313F mutant only showed ∼50% activity at 0.5-1.0 µM
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(a) Inhibition in NmeIPMS wild-type and Y313F.
(b) Inhibition in NmeIPMS wild-type and several mutants
Figure 3.11: Preliminary inhibition studies of NmeIPMS variants. Negative
values indicate activation rather than inhibition.
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Table 3.3: Summary of activity of NmeIPMS enzymes. The “change” column
refers to an n-fold increase(+) or decrease(–) in activity over the tagged wild-
type enzyme. Activities were measured under saturating conditions: 250 µM
α-KIV and AcCoA. The Km values for the wild-type enzyme are 30 µM and
35 µM respectively.
NmeIPMS- Activity (/s) Change
wild-type (untagged) 8.9 ± 0.2 —
wild-type 1.530 ± 0.002 —
R32C 3.70 ± 0.08 +2.42
D375C 3.4110 ± 0.0005 +2.229
R470A 4.120 ± 0.004 +2.67
K332A 0.024 ± 0.002 –63
Y313A 0.002 ± 0.002 –700
Y313F 0.020 ± 0.005 –80
concentrations of leucine, and greatly increased activity with 5.0 µM leucine
(Figure 3.11a). Further studies are required to investigate this unusual result.
Arg32 and Asp375 were both mutated to cysteine, and unlike the corre-
sponding mutations in MtuIPMS, neither of these mutants resulted in lowered
catalytic activity. R32C did substantially lower leucine sensitivity, indicating
this salt-bridge is important in transmitting the allosteric signal. D375C showed
an increase in leucine sensitivity at lower concentrations, and slightly decreased
sensitivity at higher concentrations. Given the relatively similar size of the
aspartate and cysteine sidechains, it is perhaps unsurprising that cysteine can
adopt a similar role in this position: presumably it is acting as a hydrogen-
bond acceptor from Arg32, propagating the allosteric signal via this bond just
as aspartate would with via a salt-bridge. In any case, we have shown that
polar interactions here are important for allostery: in future work, the double-
mutant may show whether catalysis in interrupted by locking the domains with
a disulfide bridge, perhaps shedding light on the question of domain movement
in α-IPMS enzymes.
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Mutating Lys332 was predicted to reduce leucine sensitivity, but the main
effect seems to be that it has reduced the catalytic capacity of the enzyme ∼60-
fold. Due to the low catalitic activity, no firm conclusions can be drawn as to
whether allostery has been affected. As this residue looks to be important for
keeping subdomain I in position for catalysis when leucine-binding lifts it from
the active site, it is understandable that catalysis is compromised, and more
sensitive to any disrupting influence (such as leucine binding).
As predicted, mutating Arg470 successfully removed all leucine inhibition,
without drastically altering catalytic activity, proving the importance of the
hydrogen-bonds predicted by MD simulations.
3.7 Summary
While the mutants described above have yet to be fully characterised, the
initial results provide some rather enticing insights. The bizarre interaction
of Y313F with leucine needs to be more fully explored. As well as a full
kinetic characterisation, thermal stability ought to be examined with varying
concentrations of leucine. It is possible that the decreased activity we see with
Y313F is caused by increased structural flexibility associated with the mutation:
Frantom et al.24 found several regions of MtuIPMS to have increased solvent
exposure due to the corresponding Y410F mutation. In that study, and in
previous work in this group1,52 leucine binding appears to stabilise the enzyme,
which may explain why higher concentrations of leucine restored some catalytic
ability.
Predictions regarding the properties of two mutants (K332A and R470A)
based on MD simulations were tested, and preliminary results suggest the
simulations accurately reflect motions tested in vitro. Allosteric inhibition was
completely destroyed in K332A, with no decrease in catalytic activity. This
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indicates the predicted salt-bridges are essential for relaying the allosteric signal
away from the regulatory domain. Arg470 appears to be a crucial residue for
maintaining catalytic activity, and a more thorough exploration of its kinetics
ought to shed more light on whether it also plays a role in allostery.
Unlike the cysteine mutants previously studied in MtuIPMS, the NmeIPMS
mutants (R32C and D375C) showed no evidence (at this preliminary stage)
that the mutations harm catalysis. Interrupting the predicted salt-bridge does
appear to decrease leucine sensitivity, although due to cysteine’s ability to
form hydrogen bonds, future work should confirm this by mutating to alanine.
Another area to explore is to form a cysteine double-mutant. We predict it
should form a disulfide bridge, and by determining effect this has on catalysis, we
will hopefully shed some light on the questions surrounding domain movement
and flexibility in α-IPMS enzymes.
Chapter 4
Discussion
The aim of this work was to probe the selectivity and mechanism of allosteric
regulation in α-IPMS enzymes. We successfully altered the allosteric specificity
of MtuIPMS based on insights gained from sequence homology and crystal struc-
tures of MtuIPMS (inhibited by leucine) and LiCMS (inhibited by isoleucine)
enzymes. We also tested predictions from molecular dynamics (MD) simulations
for the roles of several residues in NmeIPMS in conducting the allosteric signal
from the regulatory domain to the catalytic site, a distance of ∼ 50Å.
The approach followed was to introduce the desired mutations to MtuIPMS
and NmeIPMS genes using site-directed mutagenesis, and extracting and puri-
fying the resultant enzymes using immobilised metal affinity and size-exclusion
chromatography. These mutant enzymes were subjected to preliminary physical
and kinetic characterisation to assess properties such as thermal stability and
inhibition by various branched-chain amino acids.
One principle goal of this study was to tune the allosteric specificity of
MtuIPMS from leucine towards isoleucine. Zhang et al.15 had previously shown
LiCMS could gain allosteric sensitivity to leucine with a single mutation: we
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hoped that using similar methods we could engineer isoleucine sensitivity into
MtuIPMS. A range of single mutants had been tested1 with partial success: a
gain in norvaline sensitivity in one mutant (A567V, which corresponds to the
V468A mutation Zhang et al. found to confer leucine sensitivity on LiCMS).
We hoped by incorporating more mutations we might also achieve an isoleucine-
sensitive α-IPMS. One of our enzymes with two mutations (A567V + I627A)
did show strong inhibition in the presence of isoleucine, and a corresponding
decrease in leucine sensitivity. Two more enzymes (A567V + V551L, and A567V
+ V551L + I627A) had become allosterically promiscuous, being inhibited by a
range of branched-chain amino acids. This was achieved with only two or three
mutations to the wild-type enzyme, which may reflect the kinds of change we
would see in enzyme evolution, hinting at the close evolutionary relationship
between the CMS and α-IPMS enzymes.
Having achieved some insight into the residues mediating molecular recog-
nition at the allosteric binding pocket, we were also interested in exploring the
signal-transduction pathway between the allosteric and catalytic sites. This
has been investigated by De Carvalho, Frantom, and colleagues24,29,53,54 by
mutagenesis and hydrogen-deuterium exchange experiments.
Koon et al.9 suggested the highly conserved Tyr410 residue in MtuIPMS
had a catalytically important function, orientating His379 to act as a base in
catalysis. Frantom et al.24 found Tyr410 to be essential for allosteric regula-
tion in MtuIPMS, as substitution with phenylalanine mimicked a completely
inhibited state in the enzyme, with a large decrease in catalytic rate that was
unaffected by leucine.
We found that the corresponding residue in NmeIPMS (Tyr313) was indeed
critical for catalysis, as substitution with alanine severely curtailed enzymatic
activity. However, when phenylalanine was substituted instead, the enzyme still
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showed sensitivity towards leucine: moderate inhibition at low concentrations,
and strong activation at higher concentrations. We propose that the mutation
compromises enzyme stability leading to reduced catalysis, but is somewhat
stabilised (and catalysis rescued) by higher concentrations of leucine. Assessing
the thermal stability of this mutant with varying concentrations of leucine ought
to provide a simple test of this hypothesis.
The approach adopted by Frantom et al. provides excellent experimental
insight into these systems, but little predictive power. MD simulations afford
many opportunities to generate hypotheses for experimental testing. In this
study we tested the properties of several new residues identified by MD simula-
tions as being important for allostery. These residues had not been previously
identified as they are not highly conserved, nor do they occupy any obvious
structural role.
Two such residues, Arg32 and Asp375, are predicted to form a salt-bridge
in one conformation of the asymmetric dimer, potentially affecting stability,
catalysis, or inhibition. By substituting each residue for cysteine, we found
that the salt-bridge does not appear to be important for catalysis, but does
appear to be part of the allosteric communication pathway between regulatory
and catalytic domains. We would expect a double-mutant to form a disulfide
bridge, restricting movement between domains. The effect this might have on
catalysis or allostery may help to shed light on the role of domain movements
in α-IPMS enzymes.
Another residue predicted to be involved in domain movements, albeit more
subtle, was Lys332. MD simulations suggested it was involved in the movement
of subdomain I away from the catalytic barrel upon leucine binding. By mutat-
ing this residue to alanine, we found evidence that rather than being responsible
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for this movement and inhibition, Lys332 appears instead to stabilise subdomain
I near the active site, moderating the effects of leucine binding.
The final residue tested, Arg470, was shown to play a key role in transmitting
the allosteric signal out of the regulatory domain. MD simulations predicted
altered hydrogen-bonding of this residue upon leucine binding, and we found
that mutating it to alanine completely eliminated leucine inhibition.
While we have achieved some fascinating insights into the selectivity and
mechanism of allostery in two α-IPMS enzymes, full kinetic characterisation
of our mutants should provide more robust evidence for what we have found,
allowing stronger conclusions to be drawn. Futher investigation into the Arg32
/ Asp375 mutants, and construction and testing of a double-mutant, should
provide some interesting clues as to the role of domain movements in α-IPMS.
To conclusively test whether a pendulum-like rearrangement occurs, we
would need to explore a Förster Resonance Energy Transfer (FRET) based
technique,55 in particular, single-molecule FRET.56,57 Introducing two different
fluorescent labels onto the dimer could prove difficult. Mutating surface residues
to cysteine would allow us to add the labels but we would have to find a way
to selectively protect and deprotect these residues in order to bind separate
fluorescent donor and acceptor groups.58 Cell-free translation systems offer
greater control59 but require elaborate preparations. Perhaps the best approach
would be to express the N- and C-terminal regions of NmeIPMS separately,
label them, then use chemical ligation60 to reconstitute the full-length enzyme.
The labelling steps would have to be conducted with a stoichiometric excess of
enzyme, to minimise the number of enzymes with both chains labelled.
Gaining a better understanding of the catalytic and regulatory functions
of enzymes have diverse possible applications: improving enzymes for green
chemical processes,61–64 as biosensors,13,65,66 and designing enzyme inhibitors
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for drug development.12,67 The approaches followed here are simple, and yet
show the power we have to alter enzymes to suit our needs. This dynamic and
emerging field is increasing using a combination of rational models, sequence-
based data (including “smart” methods such as ProSAR68), and MD simu-
lations69–71 to open up exciting new avenues to improved therapeutics, and





All buffers and solutions were made using reverse-osmosis water treated with a
Millipore Milli-Q system prior to use.
5.1.2 pH
The pH of buffers and solutions was measured using a Mettler Toledo Seven-
Compact pH meter, and adjusted by addition of NaOH or HCl.
5.1.3 Concentration Determination of DNA & Proteins
Concentration of DNA was measured spectrophotometrically at 260 nm using a
Nanodrop® ND-1000 spectrophotometer. Concentration of protein was estab-
lished similarly at 280 nm, using extinction coefficients from Section 5.5.1.
69
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5.1.4 Protein Structure Images
Protein structures were viewed, and images prepared using The PyMOL Molec-
ular Graphics System, Version 1.5.0.4 Schrödinger, LLC.72
5.1.5 Multiple Sequence Alignments
Multiple sequence alignments were created using Clustal Omega46 and Jalview.45
5.2 Microbiology
5.2.1 Cell Lines
E. coli OneShot® TOP10 (Life Technologies), DH5α™(Life Technologies), XL1-
Blue (Stratagene), or Stellar™ Competent Cells (Clontech) were used for plasmid
propagation. For protein expression, E. coli OneShot® BL21 Star (DE3) (Life
Technologies) cells were used for NmeIPMS proteins and Rosetta 2 (Novagen®)
cells for MtuIPMS proteins.
5.2.2 Glycerol Stocks
Cell lines of interest were preserved as glycerol stocks at -80°C. A 5 mL LB cul-
ture containing appropriate antibiotics, innoculated from a single colony from an
agar plate, was grown overnight, and 0.8 mL of this was added to 0.4 mL sterile
50% glycerol solution (molecular biology grade) in a sterile microcentrifuge tube.
After inverting to mix, the tube was labelled and frozen in liquid nitrogen before
storage.
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5.2.3 Culture Media
LB was used as the standard growth medium for expression and propagation
strains, while SOC media was used for transformations. All media was made




Yeast extract 5 g/L
NaCl 5 g/L
For LB-agar, 15 g/L agar was added prior to autoclaving. LB-agar was
melting in a microwave and cooled until approximately 50°C. In a sterile laminar
flow cabinet, antibiotics were added as appropriate, and the medium was poured
into five or six sterile plastic petri dishes. Once cooled, the plates were used
straight away, or wrapped in plastic and stored at 4°C for up to two weeks before
use. Stored plates were warmed at 37°C before use.
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Super Optimal Broth with Catabolite Repression (SOC) Media
Compound Amount
Tryptone 20 g/L





Autoclaved SOC was aliquoted into sterile 1.7 mL microcentrifuge tubes and
stored at 4°C until use.
5.2.4 Antibiotics
All plasmids used in this project contain an ampicillin-resistance gene, so all
cultures were grown in the presence of 100 µg/mL ampicillin. Rosetta 2 cells
are chloramphenicol resistant, so also had 25 µg/mL chloramphenicol added.
Antibiotics were stored in sterile microcentrifuge tubes at -20°C or -80°C as a
1000x stock. Chloramphenicol stock was made up in 100% AnalaR ethanol,
while ampicillin was made up in either Milli-Q or 50% AnalaR ethanol.
5.3 Genetic Manipulation
5.3.1 Plasmid Extraction
Plasmids were extracted from overnight LB cultures containing appropriate
antibiotics, innoculated from either a single colony from an agar plate, or from a
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frozen glycerol stock scraping. Approximately 3 mL of the resulting culture was
processed using either a NucleoSpin® Plasmid EasyPure kit (Machery-Nagel)
or High Pure Plasmid Isolation Kit (Roche). Plasmids were assessed for purity
by 260 nm/280 nm absorption measurement and by agarose gel electrophoresis
(see section 5.3.3) before being stored at -20°C.
5.3.2 Chemical Transformation
Chemically Competent Cells
To make chemically competent cells, a 5 mL overnight LB culture (with antibi-
otics as appropriate) was innoculated with a frozen glycerol stock scraping and
incubated at 37°C. Around 2 mL of this culture was then used to innoculate
100 mL LB (and antibiotics), which was then grown until an OD600 ∼ 0.4 was
reached. The culture was then chilled on ice for at least 30 minutes. Cells were
harvested at 3000 rpm (4°C) for 15 minutes in chilled 50 mL sterile centrifuge
tubes, and the supernatant discarded. The cells were then kept on ice, and
resuspended in 20 mL of chilled, autoclave-sterilised 50 mM CaCl2 + 15%
(v/v) glycerol. The cells were incubated on ice for 30 minutes before being
harvested again at 3000g as before. The supernatant was discarded and the
pellet resuspended on ice in 4 mL CaCl2/glycerol before being aliquoted out
into sterile, chilled 1.5 mL centrifuge tubes and frozen in liquid nitrogen. Cells
were stored at -80°C until required.
Transformation of Competent Cells
Aliquots of cells were thawed on ice, then up to 5 µL of plasmid or DpnI-digested
SDM product was gently mixed in, and the incubated for 30 minutes on ice. The
tube was then heat-shocked for 30s in a 42°C waterbath, chilled on ice briefly,
CHAPTER 5. MATERIALS AND METHODS 74
then incubated at 37°C with 500 µL SOC medium. This was then plated onto
LB-agar plates with appropriate antibiotics and grown at 37°C.
5.3.3 Agarose Gel Electrophoresis
Agarose gels (1%) were prepared by adding 0.3 g molecular biology-grade agarose
in 30 mL TAE buffer and microwaving until dissolved. After allowing several
minutes to cool, 3 uL SYBR® Safe was added and the gel poured. Samples
were mixed on a piece of Parafilm® M with 6x DNA loading buffer before being
loaded onto the gel, which was then run in TAE buffer at 85-100 V for 30-45
minutes in a Mini-Sub® Cell GT (Bio-Rad). Gels were visualised under UV
light in a Molecular Imager® Gel Doc™ XR (Bio-Rad).
TAE Buffer (50x) DNA Loading Buffer (6x)
Compound Amount Compound Amount
Tris Base 242g Tris-HCl 60 mM
Disodium EDTA 18.6 g EDTA 60 mM
Glacial acetic acid 57.1 mL Orange G 0.2% (w/v)
Xylene Cyanol FF 0.05% (w/v)
Glycerol 60% (v/v)
Made up to 1 L in Milli-Q
5.3.4 Polymerase Chain Reaction
Taq DNA Polymerase (Roche) was sometimes used to check the integrity of
mutated plasmids or reliability of primers before sequencing. 20-50 µL reac-
tions were prepared according to manufacturer’s instructions, and thermocycling
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carried out in either a Veriti® 96-well Thermal Cycler (Applied Biosystems)
or an iCycler (Bio-Rad). For MtuIPMS-derived templates, 3% DMSO was
typically added to the reaction to help overcome the high G+C content typical
of Mycobacterium genes.
5.3.5 Site-Directed Mutagenesis (SDM)
SDM was typically carried out in 20-50uL reactions using Phusion® High-
Fidelity DNA Polymerase (New England BioLabs Inc.®). Around 100ng tem-
plate plasmid was used per reaction, 5pmol of each forward and reverse mutage-
nesis primer, and dNTPs etc. as per manufacturer’s instructions. For NmeIPMS
templates the supplied HF buffer was used, whereas for MtuIPMS the GC buffer
and 3% DMSO were helpful in overcoming the high G+C content. Thermocy-
cling was as per manufacturer’s instructions, using an annealing temperature of
55°C. The SDM product was incubated for 1-2 hours at 37°C in the presence
of Dpn I enzyme (either Roche, Life Technologies, or New England BioLabs
Inc.®) to digest the template. The resultant digest was transformed into either
TOP10 or Stellar Competent Cells for plasmid propagation. Several colonies
were picked for plasmid extraction, and the resultant plasmids and their PCR
products were typically checked by agarose gel electrophoresis before being sent
for sequencing.
5.3.6 DNA Sequencing
Sequencing was performed by either Canterbury Sequencing or Massey Genome
Services. Canterbury use an ABI3100 Genetic Analyzer (Applied Systems Inc.)
and a procedure based on Sanger chain-termination protocol. Plasmids were
provided submitted at 100ng/uL and primers at 3.2 µM. Massey use an ABI3730
DNA Analyzer and BigDye™ Terminator chemistry. Plasmid and template were
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provided pre-mixed in 20 µL volumes containing 350-600ng plasmid and 4pmol
primer.
5.3.7 Primers for Sequencing & Mutagenesis
Primers for mutagenesis were designed using PrimerX73 and synthesised by Life
Technologies. Primers were delivered lyophilised, and were reconstituted and
stored in TE buffer (10 mM Tris-HCl, 100 mM EDTA). A full list of primers
used is found in Table Table 5.1.
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5.4 Protein Expression & Purification
5.4.1 Protein Expression
A scraping from a glycerol stock was used to innoculate 5 mL LB + ampicillin
preculture, which was grown overnight. This was then used to innoculate
(typically) 1L of LB + ampicillin, which was then grown at 37°C until an
OD600 of 0.4-1.0 was reached. Expression was induced with 0.25 mM IPTG
and the culture left to grow at 23°C overnight. Cells were typically harvested
by centrifugation at 14,000 g for 30 minutes at 4°C before being frozen and
stored at -80°C.
5.4.2 Protein Extraction
Cell pellets were thawed at room temperature and resuspended in chilled, 0.2 µM
filtered lysis buffer (50 mM potassium phosphate, 300 mM KCl, pH 8.0). Usually
around 25 mL of buffer was used for a pellet from 1L culture. Cells were lysed us-
ing an Omni-Ruptor 4000 Ultrasonic Homogenizer (Omni International). Cells
were kept on ice during sonication, which was performed at 70% power, 40%
duty cycle, for cycles of 5 minutes. Cells were allowed to cool between sonica-
tions. Sonication progress was monitored by eye - usually the consistency was
noticeably thinner after 3-4 cycles. At this stage, Benzonase® Nuclease (Sigma)
was added and the soluble protein fraction was separated by centrifugation
(40,000 g, 30 minutes at 4°C). If lysate was to be kept for over an hour, one
cOmplete Protease Inhibitor Cocktail Tablet (Roche) was added per 50 mL
lysate.
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5.4.3 FPLC Chromatography
All chromatography was performed using a Bio-Rad BioLogic DuoFlow, either
at 4°C or on the bench using ice-chilled buffers and collection tubes in an ice-
bath. Elution of protein was followed by UV absorption (benchtop unit) or
280 nm absorption (4°C unit). Samples were typically injected onto columns
using a 10 mL or 50 mL Superloop™ (GE Healthcare).
5.4.4 Immobilised Metal Affinity Chromatography (IMAC)
Separation of Tagged Protein
Crude lysate was loaded onto a 5 mL Histrap HP (GE Healthcare) IMAC column
equilibrated with lysis buffer. Using the Duoflow units’ buffer mixing capability,
imidazole concentrations could be varied between 0-500 mM using lysis buffer
on one pump and elution buffer (lysis buffer + 500 mM imidazole, pH adjusted
to 8.0) on the other. The column was washed with 10 column volumes of 20 mM
imidazole to remove any non-specificly bound protein. Bound protein was then
eluted using an imidazole concentration gradient increasing to 500 mM imidazole
over ten column volumes.
5.4.5 Sample Concentration, Desalting, & Buffer Exchange
For concentrating and desalting or buffer exchanging protein samples, 10kDa
centrifugation concentrators (GE Healthcare, Sartorius, or Millipore) were used
in centrifuges cooled to 4°C. For larger volumes or faster buffer exchanging /
desalting, a HiPrep 26/10 Desalting chromatography was used (GE Healthcare)
equilibrated with the appropriate final buffer.
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5.4.6 His-Tag Cleavage
To remove the His-tag, protein samples were desalted or buffer exchanged to
remove imidazole, then 1 mM DTT and 0.5 mM EDTA were added, along with
0.1-1 mg of TEV protease per 10 mg tagged protein. Samples were typically
incubated on the bench for 30-60 minutes then overnight at 4°C. Treated samples
were then desalted to remove EDTA and loaded onto a HisTrap. Cleaved protein
elutes in the wash step, while uncleaved protein, cleaved tags, and TEV protease
remain bound to the column.
TEV Protease Purification
Recombinant TEV protease74 was purified in a similar method to the other
enzymes in this work. BL21 (DE3) Star cells transformed with pRIL (rare-codon
production) and pRK793 (expressing TEV protease) were grown and expressed
in LB with chloramphenicol and kanamycin as above. Extraction and HisTrap
separation was performed as above, except 500 mM NaCl was used in buffers
instead of 300 mM KCl. Eluted protein was buffer-exchanged into storage buffer
(50 mM potassium phosphate, 200 mM KCl, 10 mM DTT, 2 mM EDTA, pH
8.0), concentrated to ≈ 1.5 mg/mL, and glycerol added to 10% (v/v), before
being flash frozen in aliquots of 1 mg total protein.
5.4.7 Size-Exclusion Chromatography
As a final purification step, samples were loaded onto a Superdex 200 26/60
column (GE Healthcare) equilibrated with 10 mM Tris (pH 8.0) and eluted at
1.0 mL/min. Protein-containing fractions were checked for purity by SDS-PAGE
before being pooled and stored.
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5.4.8 Protein Storage
Pure protein samples were concentrated to ≥ 1 mg/mL before being flash frozen




The parameters displayed in Table Table 5.2 were calculated using the Prot-
Param75 tool on the Expasy web server. The MtuIPMS mutants included an
N-terminal gly-ala remnant from the His-tag. NmeIPMS proved very resistant
to His-tag cleavage, so the wild-type was purified in both cleaved and tagged
form, but the others were only purified with the tag intact. The tagged enzymes
had MHHHHHHGKPIPNPLLGLDSTENLYFQGA (MtuIPMS) or MHHHHH-
HGKPIPNPLLGLDSTENLYFQGIDPFT (NmeIPMS) before their sequence,
while the cleaved WT protein had only the residues indicated in bold.
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NmeIPMS wild-type 56,027 24,660







* His-tag not cleaved.
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5.5.2 Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE was used during purification to check protein purity. Samples were
mixed with Bolt® sample loading buffer and DTT then boiled for 5 minutes,
then loaded onto Bolt® Bis-Tris Plus precast gels (Life Technologies). Gels
were run in Bolt® MES or MOPS SDS Running Buffer in a Mini Gel Tank
(Life Technologies) at 165-200V for 30-45 minutes. Gels were then heated
in a microwave oven with stain (1% Coomassie Brilliant Blue R-250, 40%
methanol, 10% acetic acid) and shaken for 5-10 minutes before being destained
(40% methanol, 10% acetic acid) with heating and shaking as before, until the
background stain had been sufficiently reduced. Gels were stored in RO water
until ready for photographing on a Molecular Imager Gel Doc XR (Bio-Rad).
5.5.3 Mass Spectrometry
Samples were desalted into either Milli-Q water or 5 mM ammonium bicarbonate
using centrifugation concentrators (Vivaspin® by Vivaproducts or Nanosep®by
PALL®) and analysed using Bruker maXis 3G mass spectrometer by the Uni-
versity of Canterbury Chemistry Department.
5.5.4 Circular Dichroism Spectrophotometry
Samples were analysed using a JASCO J-815 Spectropolarimeter. Samples
were diluted in a 1 cm pathlength, 3 mL quartz cuvette with Milli-Q water
to approximately 0.05 mg/mL and this was adjusted as necessary to achieve the
best data signal. Samples were scanned from 190 - 260 nm with 2 nm pitch,
1 second response, and 1 mM bandwidth, at room temperature. Spectra were
smoothed and a blank (pure Milli-Q) was subtracted using the supplied JASCO
software. Data were scaled before being overlayed to compensate for slightly
varying concentrations used.
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5.5.5 Differential Scanning Fluorimetry
Differential Scanning Fluorimetry was carried out in a Bio-Rad iCycler™ Real-
Time PCR Detection System. Samples were made up in triplicate 25 µL volumes
prepared in a 96-well plate on ice. Before analysis, the plate was sealed and
centrifuged briefly, then analysed using a thermal melt program on the iCycler®
starting at 20°C and increasing by 0.5°C steps (with a 30s hold time) up to 95°C.
Control wells were also analysed with all sample components except protein,
which was substituted with Milli-Q. Sample components listed below.
Assay Component Volume (µL)
50 mM BTP (pH 8.0) 20
250x SYPRO® Orange dye (Sigma) 1
Protein sample (1 mg/mL) 4
Total 25




Kinetic assays were performed using a Varian Cary 100 UV-Vis spectropho-
tometer fitted with temperature controller, and the Cary WinUV Kinetics Ap-
plication (Version 3, Varian). Initial rates were measured using this application
by least-squares fit. Either 2 mM pathlength or black-walled 1 cm pathlength
quartz cuvettes were used for all assays. All assays were carried out at 25°C.
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5.6.2 Coupled Assay
Adapted from the method from de Carvalho et al ,49 the formation of CoA
was followed by its reaction with DTP, producing a species which absorbs at
324 nm (Beer-Lambert Law, A = εcl, where ε = 1.98 × 104 M-1 cm-1). A
typical assay would include 0-250 µM AcCoA, 0-250 µM α-KIV, and 100 µM
DTP made up in 1 mL of assay buffer (50 mM HEPES, 20 µM KCl, 20 µM
MgCl2, pH 7.5) brought to temperature and initiated by addition of enzyme.
Enzyme concentrations were usually ≈ 100 nm, resulting in reaction rates ≤
0.1 Abs/min. Reaction rates were converted from Absorbance units/min to
µM/min via the Beer-Lambert Law. Reactions were carried out in duplicate,
and repeated if variance greater than 10% between replicates was observed.
Assay Buffer Concentration Assay Component Concentration
HEPES 50 mM AcCoA 0-250 µM
KCl 20 mM α-KIV 0-250 µM
MgCl2 20 mM DTP 100 µM
pH 7.5 Assay buffer Made up to 1 mL
Substrate Concentration Determination
To find the concentration of AcCoA and α-KIV, a limiting amount of the
substrate of interest was added to a reaction cuvette, with the other substrate
in excess. The total change in absorbance seen over the course of the reaction
(∆Areaction) was measured in triplicate. The change in absorbance after adding
enzyme to the assay buffer with no substrate present was measured as a control
(∆Aenzyme). The corrected change in absorbance (∆Areaction−∆Aenzyme) was
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used with the extinction coefficient (ε = 1.98 × 104 M-1 cm-1) and the Beer-
Lambert Law to determine the concentration of the limiting substrate.
Inhibition Studies
For inhibition assays, the reaction was initiated by addition of AcCoA rather
than enzyme. In this case the reaction mixture (including enzyme, α-KIV,
and the amino acid being tested for inhibition) was incubated at 25°C before
initiation, to control for the slow-onset inhibition seen in this enzyme. Amino
acid concentration was varied between 0, 0.5, 1.0, and 5.0 mM. The reduction
in activity was calculated as (Rate0 − Ratei)/(Rate0) × 100%, where Rate0
is the rate with 0 mM amino acid added and Ratei is the rate with a given
concentration of amino acid present. AcCoA and α-KIV were kept at satu-
rating concentrations to ensure that small volume measurement errors did not
significantly affect the rates. Concentrations of 250 µM α-KIV and 425 µM
AcCoA were empirically determined to provide a satisfactory balance between
economy and reproducibility. Due to the high concentration of AcCoA required,
these experiments were conducted using 2 mM pathlength cuvettes.
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